A former lab director says Theranos 'valued PR and fundraising' over patients

Adam Rosendorff said he felt pressured to vouch for tests he did not have confidence in. His testimony appeared to tie Holmes more closely to the lab's failures.

Elizabeth Holmes

Elizabeth Holmes leaves the San Jose courthouse where her fraud trial is underway.

Photo: Jane Tyska/Digital First Media/The Mercury News via Getty Images

Former Theranos lab director Adam Rosendorff testified Friday that he repeatedly raised the alarm about bad blood tests to then-CEO Elizabeth Holmes, ultimately concluding that the company valued press and funding more than the patients.

"I was very enthusiastic working at Theranos in the beginning. Over time, I came to realize that the company really valued PR and fundraising above patient care, and I became very disillusioned," Rosendorff said on the witness stand inside the San Jose courtroom where Holmes' trial on fraud charges began this month.

The testimony of the Theranos lab director repeatedly tied Holmes to the problems at the Theranos lab, showing the CEO was well aware of the issues and included directly in complaints about the quality of the tests. She is facing charges of fraud and conspiracy to commit fraud against patients and investors. In order to prove its case, the U.S. government has to convince the jury to agree that Holmes had an intent to deceive and reject the defense's argument that she was a young CEO whose startup failed to live up to its promise.

During his testimony, Rosendorff said he felt pressured by upper management to vouch for tests he felt were "wrong." Holmes, accused co-conspirator Sunny Balwani, Daniel Young and Holmes' brother Christian were "pushing" him to rationalize or justify erroneous results, he testified: "Anything other than saying our test is inaccurate."

"At one point I started to refuse to talk to physicians. I believe I told one or two physicians that I didn't believe in the results," he added.

Rosendorff joined Theranos in early 2013 before Theranos tests were commercially available, and he was intrigued by the idea of running tests on a fingerprick of blood. "I thought it was going to be the next Apple," he said.

By that summer, a few months after joining, Rosendorff was already looking for a new job. Theranos had struck a deal with Walgreens to test patients' blood inside of the stores and was gearing up for a commercial launch in September 2013. But emails entered as evidence in the case showed that even nine days before the launch, none of Theranos' proprietary tests had been validated for use on patients.

Rosendorff raised the alarm specifically with Holmes, sending an email titled "Concerns about the launch" and asked her to delay it for a few weeks. He recounted that he met directly with Holmes in her office after the email, where she had taped on her window a paper countdown of the number of days left until going live.

"She was not her usual composed self. She was trembling," he said. When he raised his concerns, he said Holmes did not seem surprised to hear them, but was "nervous and upset." Despite his reservations, the launch went ahead as planned.

Rosendorff's concerns about the tests only amplified from there. During the roughly six hours of testimony, Assistant U.S. Attorney John Bostic spent much of it going over the accuracy of several Theranos tests that were run on its own devices or modified third-party machines. The tests included hCG levels, which are crucial to determine pregnancy, as well as cholesterol and potassium levels.

In each case, Rosendorff had expressed concern about tests being out of range, often failing quality control, and ultimately delivering incorrect results to the patients. One example which had come up in earlier testimony was about a pregnant patient whose results wrongly told her she was miscarrying when she in fact was still pregnant. Rosendorff told Holmes he was "freaking out" about the problems with the hCG tests, but she didn't seem alarmed, he said.

In an all-caps email in May 2014, Rosendorff made the call to ban the lab from running the hCG tests on Theranos devices and insisted they use the third-party devices from other manufacturers. It wasn't until he was shown emails during testimony that he found out that some employees had continued to use Theranos' proprietary devices against his orders.

In another case, the company returned potassium levels and sodium levels out of the typical ranges for blood tests far more often than he had seen in other labs. Eventually Theranos stopped reporting the results of any patients whose levels were outside of the expected ranges for certain tests like sodium.

In an email to Holmes, Rosendorff questioned the utility of the test for patients if abnormal results couldn't be delivered to the patient: "I am not sure of the clinical value of a sodium assay in which the only time as we can report it is when it is not critical, and the very situations that require accurate measurement and reporting of abnormal sodium results are voided."

Instead of removing the sodium test from the order menu, Theranos decided to simply report to patients that the results were voided and made it seem like a temporary thing, he said. Rosendorff felt like this was misleading doctors, because often they would specifically be testing for those things if they had come out of range.

Ultimately, Holmes' brother Christian, who handled customer complaints at the lab, also raised concerns directly to his sister in a September 2014 email. "I am always confident in our technology, but it's pretty obvious we have issues with calcium, potassium and sodium specifically," he wrote.

By that point, Rosendorff said he had entirely lost confidence in the technology and that the issue was broader than the three tests.

Eventually, Rosendorff started forwarding messages that documented concerns with a variety of tests to his personal Gmail account, in violation of the company's nondisclosure agreements.

"I wasn't confident that Theranos would preserve these emails in the event of a CMS and government investigation," Rosendorff said, referring to the agency that regulated labs like Theranos. "I wanted to protect myself."

He eventually left Theranos at the end of 2014, disillusioned by the startup that he once thought would be the next Apple. Today, Rosendorff doesn't even list Theranos on his LinkedIn by name.

Rosendorff's testimony is expected to continue in the Theranos trial on Tuesday. Follow Protocol's coverage of the Theranos trial here.


Judge Zia Faruqui is trying to teach you crypto, one ‘SNL’ reference at a time

His decisions on major cryptocurrency cases have quoted "The Big Lebowski," "SNL," and "Dr. Strangelove." That’s because he wants you — yes, you — to read them.

The ways Zia Faruqui (right) has weighed on cases that have come before him can give lawyers clues as to what legal frameworks will pass muster.

Photo: Carolyn Van Houten/The Washington Post via Getty Images

“Cryptocurrency and related software analytics tools are ‘The wave of the future, Dude. One hundred percent electronic.’”

That’s not a quote from "The Big Lebowski" — at least, not directly. It’s a quote from a Washington, D.C., district court memorandum opinion on the role cryptocurrency analytics tools can play in government investigations. The author is Magistrate Judge Zia Faruqui.

Keep ReadingShow less
Veronica Irwin

Veronica Irwin (@vronirwin) is a San Francisco-based reporter at Protocol covering fintech. Previously she was at the San Francisco Examiner, covering tech from a hyper-local angle. Before that, her byline was featured in SF Weekly, The Nation, Techworker, Ms. Magazine and The Frisc.

The financial technology transformation is driving competition, creating consumer choice, and shaping the future of finance. Hear from seven fintech leaders who are reshaping the future of finance, and join the inaugural Financial Technology Association Fintech Summit to learn more.

Keep ReadingShow less
The Financial Technology Association (FTA) represents industry leaders shaping the future of finance. We champion the power of technology-centered financial services and advocate for the modernization of financial regulation to support inclusion and responsible innovation.

AWS CEO: The cloud isn’t just about technology

As AWS preps for its annual re:Invent conference, Adam Selipsky talks product strategy, support for hybrid environments, and the value of the cloud in uncertain economic times.

Photo: Noah Berger/Getty Images for Amazon Web Services

AWS is gearing up for re:Invent, its annual cloud computing conference where announcements this year are expected to focus on its end-to-end data strategy and delivering new industry-specific services.

It will be the second re:Invent with CEO Adam Selipsky as leader of the industry’s largest cloud provider after his return last year to AWS from data visualization company Tableau Software.

Keep ReadingShow less
Donna Goodison

Donna Goodison (@dgoodison) is Protocol's senior reporter focusing on enterprise infrastructure technology, from the 'Big 3' cloud computing providers to data centers. She previously covered the public cloud at CRN after 15 years as a business reporter for the Boston Herald. Based in Massachusetts, she also has worked as a Boston Globe freelancer, business reporter at the Boston Business Journal and real estate reporter at Banker & Tradesman after toiling at weekly newspapers.

Image: Protocol

We launched Protocol in February 2020 to cover the evolving power center of tech. It is with deep sadness that just under three years later, we are winding down the publication.

As of today, we will not publish any more stories. All of our newsletters, apart from our flagship, Source Code, will no longer be sent. Source Code will be published and sent for the next few weeks, but it will also close down in December.

Keep ReadingShow less
Bennett Richardson

Bennett Richardson ( @bennettrich) is the president of Protocol. Prior to joining Protocol in 2019, Bennett was executive director of global strategic partnerships at POLITICO, where he led strategic growth efforts including POLITICO's European expansion in Brussels and POLITICO's creative agency POLITICO Focus during his six years with the company. Prior to POLITICO, Bennett was co-founder and CMO of Hinge, the mobile dating company recently acquired by Match Group. Bennett began his career in digital and social brand marketing working with major brands across tech, energy, and health care at leading marketing and communications agencies including Edelman and GMMB. Bennett is originally from Portland, Maine, and received his bachelor's degree from Colgate University.


Why large enterprises struggle to find suitable platforms for MLops

As companies expand their use of AI beyond running just a few machine learning models, and as larger enterprises go from deploying hundreds of models to thousands and even millions of models, ML practitioners say that they have yet to find what they need from prepackaged MLops systems.

As companies expand their use of AI beyond running just a few machine learning models, ML practitioners say that they have yet to find what they need from prepackaged MLops systems.

Photo: artpartner-images via Getty Images

On any given day, Lily AI runs hundreds of machine learning models using computer vision and natural language processing that are customized for its retail and ecommerce clients to make website product recommendations, forecast demand, and plan merchandising. But this spring when the company was in the market for a machine learning operations platform to manage its expanding model roster, it wasn’t easy to find a suitable off-the-shelf system that could handle such a large number of models in deployment while also meeting other criteria.

Some MLops platforms are not well-suited for maintaining even more than 10 machine learning models when it comes to keeping track of data, navigating their user interfaces, or reporting capabilities, Matthew Nokleby, machine learning manager for Lily AI’s product intelligence team, told Protocol earlier this year. “The duct tape starts to show,” he said.

Keep ReadingShow less
Kate Kaye

Kate Kaye is an award-winning multimedia reporter digging deep and telling print, digital and audio stories. She covers AI and data for Protocol. Her reporting on AI and tech ethics issues has been published in OneZero, Fast Company, MIT Technology Review, CityLab, Ad Age and Digiday and heard on NPR. Kate is the creator of RedTailMedia.org and is the author of "Campaign '08: A Turning Point for Digital Media," a book about how the 2008 presidential campaigns used digital media and data.

Latest Stories